Randomized Controlled Trial Comparing Embryonic Quality in rFSH Versus hMG in IVF Protocol With GnRH Antagonist
Condition: Infertility
MeSH terms: Infertility
Study type: Interventional
Phase: Phase 4

Summary: 
      rFSH and HMG are both used to controlled ovarian stimulation for patients submitted to IVF.
      However, there is a debate in the literature which one is better to induce ovulation in
      patients receiving GnRH antagonist to block premature Luteinizing Hormone (LH) secretion.

      The investigators propose a Randomized Clinical Trial (RCT) to investigate the differences
      among recombinant FSH and HMG in patients submitted to IVF using GnRH antagonists.
    

Detailed description: 
      To compare embryonic quality and other clinical outcomes when using human menopause
      gonadotropin (hMG) or recombinant follicle stimulating hormone (rFSH) to the ovarian
      stimulation in IVF cycles with the GnRH antagonist protocol.

      Design: open randomized single center study with infertile patients submitted to IVF
      comparing IVF outcomes between hMG and rFSH when controlled with GnRH antagonist.

      Setting: A single private center of reproductive medicine in association with Universidade
      Federal do Rio Grande do Sul.

      Patients: Infertile women with normal ovarian reserve with IVF indication. Intervention: The
      patients were randomized in two groups, 85 received rFSH and 83 received hMG to ovulation
      induction, both groups used GnRH antagonist to prevent ovulation.

      Main Outcome Measure: Total embryonic score and best embryonic score. Secondary outcomes:
      Total dose of gonadotropins, number and size of follicles in the end of the stimulation,
      number of mature oocytes, number of embryos, pregnancy rates.
    

Intervention name(s): rFSH; HMG
Intervention type(s): Drug; Drug
Intervention description(s): the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and antral follicle count (AFC). This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days; the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and AFC. This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
Other intervention name(s): Puregon®, Organon Ltd., Irlanda; Menopur
Intervention MeSH terms: Menotropins
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: follicular stimulating hormone; human menopausal gonadotrophin; Recombinant follicular stimulating hormone (rFSH); Gonadotrophin releasing hormone (GnRH) antagonists; GnRH agonist; in vitro fertilization; controled ovarian stimulation; number of mature oocytes